This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%
by Zacks Equity Research
Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Ironwood Pharmaceuticals, Inc. (IRWD).
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock
by Zacks Equity Research
Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 300.00% and 36.62%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Amends Linzess Agreement with AstraZeneca in China
by Zacks Equity Research
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
by Zacks Equity Research
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Investors Can Find Big Returns with this First Profit Screen
by Benjamin Rains
We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study
by Zacks Equity Research
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.
Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 214.29% and 12.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Jun 20, 2019
by Zacks Equity Research
Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD
Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
by Zacks Equity Research
Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
by Zacks Equity Research
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
by Zacks Equity Research
Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.